Technology
Transfer FY2012
Office annual report
Page 2
UC SAN DIEGO | TECHNOLOGY TRANSFER OFFICE
Technology Transfer
at UC San Diego
patents
licenses
60
total commercial
licenses
94
U.S. patents
issued
(domestic)
173 Initial patents filed
74 Secondary U.S.
applications filed
678 U.S. applications
pending
832 active U.S. patents
*data in graphics are specific to FY2012
inventions
433
reported by UCSD
Inventors
patents
(international)
75 First foreign (PCT)
applications filed
968 foreign
applications pending
801 active foreign patents
copyrights
48
reported
70
foreign
patents issued
FY2012 ANNUAL REPORT
A Message from the Assistant Vice Chancellor
I am pleased to report another productive year for the technology transfer program at UC San Diego
for the fiscal period from July 1, 2011 to June 30, 2012. For the fourth consecutive year, more than
400 innovations were reported, reaching an all-time high of 481 innovations (433 inventions and 48
copyrights), compared to 416 in FY2011.
The university’s strong research reputation continues to be bolstered by the increased number of
innovations that originate from UCSD faculty and researchers. These innovations are central to the
more than 700 agreements that were negotiated and executed by the Technology Transfer Office
(TTO) in FY2012. The agreements comprise administrative, letter, option, license, inter-institutional,
inter-office, confidentiality, and outgoing material transfer agreements (MTA). Outgoing MTAs comprise the majority with 357 agreements, a slight increase compared to 333 MTAs in FY2011.
TTO entered into 60 licensing agreements (44 inventions and 16 copyrights/trademarks) in FY2012.
Of these licenses, twelve were with newly formed companies adding to the more than 170 start-up
companies founded with university technology. In addition, this year’s report highlights a select
group of repeat inventors who have participated in the technology transfer program. The overall
increased activity is also reflected in an all-time high in the number of issued U.S. Patents of 94,
compared to 87 issued in FY2011. The total income received in FY2012 was $19.6 million, an
increase of nearly $840,000 when compared to FY2011.
In response to comments and suggestions from our academic and industry partners, the TTO is
introducing enhancements to better manage the university’s technology transfer program. To promote
new business development and to increase the speed of licensing technology to start-up companies,
the TTO met with internal university and external industry committees to lay the groundwork for a
streamlined licensing process. Their feedback resulted in the unveiling of the UCSD Express License
for therapeutics at the beginning of FY2013, followed by an express license for physical sciences/
engineering. The express license provides a quick 30-day application review process that can shorten
the time to execution; more information is available on our website. The TTO is also reviewing internal business processes to increase our efficiencies, provide wider access to tech transfer information
online and electronically, and better accommodate university faculty and researchers as well as our
corporate partners.
We welcome your feedback and continued support of the technology transfer program.
Jane C. Moores, PhD
Page 3
Page 4
UC SAN DIEGO | TECHNOLOGY TRANSFER OFFICE
Repeat Innovators
Propel Our Business
In FY2012 more than 400 new inventions and tangible materials were reported
to the TTO. We highlight a select group of faculty researchers who reported
multiple innovations to our office in FY2012. Their extensive activities fuel the
university’s culture of innovation and allow the eventual commercialization of
new products and treatments.
Todd Coleman is associate professor in the department of bioengineering. His research
is multi-disciplinary at its core, using tools from information theory, neuroscience,
machine learning and bioelectronics to understand – and control – interacting systems
with biological and computer parts. His research in developing multi-functional, flexible
bio-electronics is enabling wireless health applications that are minimally observable to
the user.
TODD P. COLEMAN, PHD
Associate Professor, Bioengineering
Director, Neural Interaction
Laboratory
inventions
reported
since 2007
15
Joining the university in 2011, Coleman has hit the ground running with several new
inventions reported and licensed at the university. His recent innovations in the fields of
brain-computer interaction and neurosciences have garnered media attention, as well as
interest from potential commercial partners.
inventions
reported
since 2011
5
Coleman holds BS degrees in electrical engineering and computer engineering from
the University of Michigan and MS and PhD degrees in electrical engineering from the
Massachusetts Institute of Technology.
Dr. Catriona Jamieson, named a “Rock Star of Science” by GQ Magazine for her exuberant
approach to medical research, is an outstanding member of a prolific group of university
inventors. She continues to push the envelope in stem cell research with new discoveries
that can potentially help many people. Her research focuses on myeloproliferative disorders
(MPDs) and leukemia–studying mutant stem cells and progenitor cells in myeloproliferative neoplasms that can give rise to cancer stem cells.
As the director for stem cell research at the Moores UCSD Cancer Center, Jamieson
has developed several stem cell-related technologies with funding support from the
California Institute for Regenerative Medicine (CIRM). Her recent innovations include
Biomarkers and Methods to Treat Leukemia (T-ALL) Stem Cells (Tech ID: 22552), Whole
Transcriptome Leukemia Stem Cell Signature (Tech ID: 22592), and Therapeutic Approach CATRIONA JAMIESON, PHD, MD
Assistant Professor, Medicine
Targeting Malignant Reprogramming in CML Stem Cells (Tech ID: 22540).
Director, Stem Cell Research
Jamieson received her BS and PhD in microbiology, and MD from the University of
Moores UCSD Cancer Center
British Columbia. Prior to joining the university, she was a research fellow at the Stanford
University School of Medicine.
FY2012 ANNUAL REPORT
Page 5
731
innovators
participated in the
technology transfer
disclosure process
inventions
reported
since 2003
82
Sungho Jin, professor of mechanical and aerospace engineering, is a world-renowned
researcher in the field of functional materials used in applications ranging from magnetic
devices and electronic devices to optical telecommunications networks. Jin is involved in
R&D of micro-electro-mechanical-system (MEMS) devices and materials; exploratory
bio-materials and devices; carbon nanotube materials on which future nano-scale devices
can be based; and sensor/actuator devices and technologies.
The inventor of magnet sensor materials widely used in anti-theft security tags in retail
stores, Jin’s recent innovations in the field of functional materials include: Spectrally
Selective Coatings for Concentrated Solar Power Systems (Tech ID: 22392),
Nanostructured High-Strength Permanent Magnets (Tech ID: 22391), and Inorganically
Surface Modified Polymers for Orthopaedic and Spinal Implants (Tech ID: 21954).
Jin received his PhD in materials science and engineering at UC Berkeley in 1974. He
joined the UC San Diego faculty in 2002 after a successful career at Bell Laboratories/
Lucent Technologies.
SUNGHO JIN, PHD
Professor, Mechanical & Aerospace
Engineering and Nanoengineering
Michael Karin, professor of pharmacology, is an acclaimed expert in signaling
pathways that enable cells to respond to external influences. As an inspired innovator,
Karin uses a wide variety of biochemical and whole animal approaches to examine
how growth factors, cytokines, tumor promotors, microbial products, UV radiation
and other environmental triggers regulate gene expression by elucidating the precise
pathways, checkpoints and molecules involved. One of his latest inventions reported
to the university is a New Target to Inhibit Metastasis of Colon Cancer (Tech ID:
22865).
MICHAEL KARIN, PHD
Professor, Pharmacology
inventions
reported
since 1990
39*
Karin was a cofounder of Signal Pharmaceutical (currently Celgene) and served as a
member of its Scientific Advisory Board. He also served as a member of the National
Advisory Council for Environmental Health Sciences and has been an American Cancer Society Research Professor since 1999. In addition to numerous honors, Dr. Karin
was recently awarded the Charles Rodolphe Brupbacher Prize for Cancer Research
in recognition of his studies on the role of chronic inflammation in the development
of tumors and is a member of the National Academy of Sciences and the Institute of
Medicine. He received his BSc in biology from Tel Aviv University and his PhD in
molecular biology from the University of California, Los Angeles.
* does not include 47
tangible research materials
Page 6
UC SAN DIEGO | TECHNOLOGY TRANSFER OFFICE
inventions
reported
since 2002
18
J. Andrew McCammon is a distinguished
professor of chemistry/biochemistry and
pharmacology and an investigator with
the Howard Hughes Medical Institute.
His research is focused on theoretical
and computational methods for studying
the function of biological molecules. By
modeling the structure and dynamics of
assemblies of these molecules, McCammon’s group develops insights that help in
the discovery of new pharmaceuticals.
A consummate inventor, McCammon
used advanced computational techniques
to help discover protease and integrase
inhibitors to fight Human Immunodeficiency Virus (HIV). A San Diego company
JASON SICKLICK, MD
Assistant Professor, Surgery
commercialized these inventions into new
drugs that help countless HIV patients.
His recent focus has been on neglected
diseases resulting in potential new treatments for diseases that are more prevalent
in other parts of the world, two of which
are: Novel Inhibitors of the Trypanosoma
cruzi Cysteine Protease Cruzain (Tech ID:
22546) and Potential African Sleeping
Sickness Drugs (Tech ID: 22770).
J. ANDREW MCCAMMON, PHD
McCammon received his AB in chemistry,
Distinguished Professor,
mathematics, and physics from Pomona
Chemistry & Biochemistry and
College, AM in physics from Harvard
Pharmacology
University, and PhD in chemical physics
from Harvard University.
Surgical oncologist, Dr. Jason Sicklick,
stands out among clinical researchers
with expertise in treating benign and
malignant diseases of the liver, bile
ducts, gallbladder, and pancreas, as well
as other gastrointestinal cancers and sarcomas. In addition to his clinical practice
at the Moores Cancer Center, he and
his colleagues are studying the role of
developmental signaling pathways such
as Hedgehog in cirrhosis and liver cancer
development and the role of novel allosteric kinase inhibitors in the targeting
of drug-resistant gastrointestinal stromal
tumors and melanoma.
Contributing to the progress of translational medicine, Sicklick is working
towards identifying novel therapeutic
targets for these conditions and initiating
clinical trials to investigate them.
95
postdocs
participated in the
technology transfer
disclosure process
His anticancer research has led to new
inventions that involve targets for KITdriven malignancies. KIT is a gene that
encodes for stem cell growth factor
receptor.
Sicklick received his MD from University of California, Los Angeles, and
completed his internship and residency
at Johns Hopkins University School
of Medicine. He completed a surgical
oncology fellowship at Memorial SloanKettering Cancer Center.
inventions
reported
since 2012
4
FY2012 ANNUAL REPORT
Page 7
ucsd translational drug
signal nanomedicine
stem cells medicine
transduction
design
nanomaterials
oncology w i r e l e s s b i o s e n s o r s
(search tags: copy and paste into
your search engine of choice)
inventions
reported
since 2009
17
Joseph Wang, a distinguished professor of
nanoengineering, focuses on the field of
nanobioelectronics where nanomaterials
are applied to the analysis of biomolecules.
His research interests include nanomotors
and nanoactuators, nanoscale barcodes,
nanomedicine, wearable on body sensors
and biofuel cells, bioelectronic detection
of proteins and nucleic acids, microfabrication, self-assembly of nanostructures,
microfluidic devices (Lab-on-a-chip),
nanoparticle-based bioassays, and bionanomaterials.
Moreover with a focus on clinical applications, Wang’s innovations can be useful for
the management of diabetes, point-of-care
clinical development of electrochemical
sensing devices for clinical and environmental monitoring, and implementable
in vivo glucose biosensors. His recent
innovations at the university include:
Isolation of Target Biomolecules from
Complex Samples Using Nano/Microscale
Motors (Tech ID: 21897), Temporary
Transfer Electrochemical Biosensors (Tech
ID: 22853), Acoustically Triggered Nano/
Microscale Propulsion Devices (Tech ID:
22680), and Printed Biofuel Cells (Tech
JOSEPH WANG, DSc
ID: 22380).
Distinguished Professor,
NanoEngineering
Wang was awarded his DSc in chemistry
from the Israel Institute of Technology.
Liangfang Zhang, professor of nanoengineering, embodies the varied breadth of
many university researchers. His research
covers a broad scope of multidisciplinary
areas including chemical & molecular
engineering, materials science, chemistry, nanotechnology, biotechnology, and
medicine.
LIANGFANG ZHANG, PHD
Professor, NanoEngineering
Zhang’s research interests focus on the
design, synthesis, characterization, and
evaluation of nanostructured biomaterials
for healthcare and other medical applications, particularly drug delivery to improve
or enable treatments of human diseases.
His recent inventions include: Pro-Drug
Conjugates Able to Deliver Precise Ratios
of Active Drugs (Tech ID: 21302), Biological “Cloaking” of Nanoparticles for
Cancer Drug Delivery (Tech ID: 22192),
and pH-Sensitive Stabilization of Liposomes (Tech ID: 20798).
Zhang received his PhD in chemical engineering from the University of
Illinois at Urbana-Champaign and BE
and MS degrees in chemical engineering from Tsinghua University in China.
Prior to joining the university, he was a
postdoctoral associate in the laboratory of
Professor Robert Langer at the Massachusetts Institute of Technology. In addition to
publications and patents, Zhang received
the 2009 Victor K. LaMer Award from
the American Chemical Society and the
2012 Unilever Award from the American
Chemical Society.
114
inventions
reported
since 2008
16
students
participated
in the technology
transfer disclosure
process
Page 8
UC SAN DIEGO | TECHNOLOGY TRANSFER OFFICE
New Start-ups
Drive Our Economy
Twelve new companies were founded
with university technology in FY2012.
Out of the twelve, seven companies
targeted the biomedical industry. All the
companies are based in San Diego.
CLINICAL METABOLOMICS, INC.
C
linMet Inc. provides
pharmaceutical companies
with clinically relevant insights
and practical information about drug
response and safety using metabolomics
for diabetes, kidney disease, obesity and
cardiovascular disease.
Leveraging its founder Dr. Kumar
Sharma’s extensive work in the area of
kidney disease, ClinMet offers specific
solutions in the areas of chronic kidney
disease (CKD) and diabetic kidney
disease. One in nine American adults
have chronic kidney disease and more
than 485,000 Americans have progressed
to end-stage renal disease, requiring
dialysis or a kidney transplant to stay
alive. Treatments and support for endstage renal disease is costly, with an
estimate cost of $20 billion to Medicare.
In the United States, diabetes continues
to be a growing epidemic with
approximately 26 million affected
individuals – 19 million diagnosed and 7
million undiagnosed, and 79 million with
prediabetes. As the seventh leading cause
of death in the US, diabetes has been a
financial burden on this country with a
total cost of $245 billion in 2012. Much
of the excess morbidity and mortality
associated with diabetes is related to
kidney dysfunction. It is estimated that
one of every 3 people worldwide will
develop diabetes by 2030, total costs for
diabetes and CKD will have a staggering
global impact.
Sharpening Clinical Trials
The cost of clinical trials can average
over $1.5 billion. Failed trials contribute
to these costs and lengthen the
process which heightens risks to the
pharmaceutical industry. In the current
environment of targeting medicine to the
individual (aka Personalized/Precision
Medicine), pharmaceutical companies are
increasingly partnering with companies,
like ClinMet, that provide companion
diagnostics and related insights to sharpen
the clinical trial process. By leveraging
its metabolomic platform and expertise in
kidney disease, ClinMet also assists large
pharmaceutical companies to address
the cardiovascular risk associated with
diabetes-related drug development.
The ClinMet metabolomics platform
specifically addresses:
•
•
•
Efficacy: Knowing if a drug is
impacting a disease and if there are
off-target effects
Safety: Avoiding costs associated
with late-stage failure or postapproval withdrawal
Insight: Gaining novel data into
mechanisms of action
CLINMET, INC.
3120 Merryfield Row
San Diego, CA 92121-1126
Email: info@clinmet.com
Phone: 858-242-4000
http://www.clinmet.com
Founded: 2011
Employees: 10
SCIENTIFIC ADVISORY BOARD
Kumar Sharma, MD, FAHA
Founder and Chief Scientific Advisor
William Nyhan, MD, PhD
Robert R. Henry, MD
CO-FOUNDERS & MANAGEMENT
Yesh Subramanian
President & CEO
Shoba Sharma
Vice President Data,
Analytics & Solutions
Sam Hodges
Advisor
ClinMet’s customers are now starting
to explore the significant potential the
Metabolomics platform has in drug
discovery.
inventions
reported
since 2008
7
UCSD TECHNOLOGY INNOVATOR
Kumar Sharma, MD, FAHA
Professor of Medicine
Director, Institute of Metabolomic Medicine
Director, Center for Renal Translational Medicine
FY2012 ANNUAL REPORT
Page 9
IGNYTA, INC.
IGNYTA, INC.
11095 Flintkote Avenue
Suite D
San Diego, CA 92121
Phone: (858) 255-5959
General inquiries:
info@ignyta.com
Business development inquiries:
bd@ignyta.com
http://www.ignyta.com
Founded: 2011
Employees: 9
MANAGEMENT
Jonathan E. Lim, MD
Chairman, CEO and Co-Founder
David W. Anderson, PhD
Chief Scientific Officer
Zachary Hornby
Vice President, Corporate
Development
Kurt Krummel, PhD
Director of Molecular Diagnostics
and Assay Development
Robert Shoemaker, PhD
Director of Bioinformatics
I
gnyta, Inc. is a company catalyzing
personalized medicine in autoimmune
diseases. Ignyta has licensed worldwide
rights from the University of California,
San Diego to develop and commercialize
cutting-edge work performed in Dr. Gary S.
Firestein’s lab.
Rheumatoid arthritis is a highly prevalent
disease, affecting about 2 percent of the
world’s population. Ignyta applies next
generation genomic, epigenomic, and other
molecular technologies to identify the best,
most accurate biological signatures possible to
discover, develop, validate, and commercialize
novel diagnostic tests and therapeutic drugs
for rheumatoid arthritis (RA) and other
autoimmune diseases. While rheumatologists
are able to diagnose rheumatoid arthritis in
patients with well-established disease, the
development of long-term morbidity and
mortality associated with rheumatoid arthritis
can be prevented by diagnosing and treating
patients earlier. As such, there is a current
need to develop molecular diagnostic tests
to help diagnose patients as early as possible
to intervene before serious issues begin to
develop.
Technology Platform
Ignyta’s Methylome™ is a proprietary
database and computational platform that
helps accelerate the discovery of novel
biomarkers for diagnostic and therapeutic
purposes.
Key features:
• Identification of biologically relevant
features through epigenetic analysis and
advanced statistical algorithms;
• Software quickly accesses and analyzes
massive amounts of data from internal
and worldwide genomic and epigenomic
databases;
• Database contains proprietary genomewide epigenetic profiles of relevant cell
types and blood samples from patients.
Key Benefits:
• Massive database of epigenetic data that
are available at one’s fingertips;
• Genome-wide data analyses identify
novel biological trends on a global scale;
• Generation of multiplexed panels that
reveal biomarkers which accurately
diagnose phenotypes and uncover
candidate therapeutic targets through
novel biological pathway discovery;
• Minimal a priori biological assumptions
allow the data to reveal new insights
without bias.
UCSD TECHNOLOGY INNOVATOR
Gary S. Firestein, MD
Director, Clinical and Translational Research Institute
Dean and Associate Vice Chancellor, Translational Medicine
inventions
reported
since 1995
20
Page 10
UC SAN DIEGO | TECHNOLOGY TRANSFER OFFICE
QUAD GEOMETRICS, LLC
Q
uad Geometrics, Inc. provides products
and services related to the precise measurement of various Earth parameters,
specifically gravity, sound, pressure,
and vibration. The application of
precision metrological principles has yielded
substantial and measurable improvements in:
• Energy (natural gas field exploration, monitoring, and improved recovery rates);
• Mining (precious mineral deposit valuation);
• Defense & Surveillance (nuclear test detection and deterrence, border and barrier
control);
• Basic Research in academia (geophysics and
fundamental constants).
468
inventors* received
intellectual
property income
* does not include TRM
or copyright innovators
QUAD GEOMETRICS, LLC
5042 Wilshire Blvd # 15682
Los Angeles, CA 90036
Phone: (858) 356-5864
http://www.quadgeo.com
Founded: 2011
MANAGEMENT
Mark Zumberge, PhD
Co-Founder
All four of these sectors are capital intensive
in nature with increases in efficiency, detection and monitoring translating into millions
of dollars in profit or security. With its broad
technology base, Quad Geometrics is capable
of providing unparalleled visibility and bottom
line results, now and into the future.
inventions
reported
since 1991
10
UCSD TECHNOLOGY INNOVATOR
Mark Zumberge, PhD
Research Geophysicist
Institute of Geophysics and Planetary Physics
Scripps Institution of Oceanography
Gravity meters in production, onboard,
and being deployed for offshore natural
gas reservoir monitoring.
FY2012 ANNUAL REPORT
Page 11
VOROZA, INC.
V
oroza is advancing video processing using depth-based analysis, either through
stereoscopic camera systems or depth
sensors. In the 3D field, one of the company’s targets, it has developed a high-quality,
real-time 3D scanning technology utilizing
low cost range-sensing devices. This allows
both researchers and consumers to easily
digitalize objects or scenes into intricate 3D
models. Using off-the-shelf imaging systems
(e.g., Kinect), the company uses sophisticated
algorithms to produce highly accurate depth
maps of objects. Aggregating this information
from multiple viewing perspectives allows
the generation of a full 3D model with a level
of detail that can be utilized in a wide array
of applications including: gaming, security,
healthcare, fashion, and entertainment.
Voroza “Unique Strategic Advantage”
• Existing camera and sensors are extremely underutilized
• Voroza is focusing on taking advantage of
the large and growing pool of video data
available
• Voroza can introduce new ways of using
existing devices, and improve depth information to:
• Allow interactivity, such as in gaming
• Create virtual perspectives, such as in
free-viewpoint visualization
• Efficiently transmit 3D videosVoroScan –
3D scanning
49
copyrights
earned fees
or royalties
50
tangible research
materials earned
fees or royalties
VOROZA, INC.
7479 Collins Ranch Terrace
San Diego, CA 92130-5574
Phone: (858) 397-8149
Founded: 2011
Employees: 3
inventions
reported
since 2002
55
http://www.voroza.com
MANAGEMENT
Truong Nguyen, PhD
Chief Technical Officer,
Co-Founder
Ramsin Khoshabeh, PhD
Vice President, Research &
Development
Jason Juang
Director, Engineering
Rick Gessner
Advisory Board
UCSD TECHNOLOGY INNOVATOR
Truong Nguyen, PhD
Vice Chair and Professor
Electrical and Computer Engineering
Calit2 (now Qualcomm Institute)
353
inventions
earned fees
or royalties
Page 12
UC SAN DIEGO | TECHNOLOGY TRANSFER OFFICE
Outreach and Partnering
Build Relationships
TTO organizes and participates in events and meetings throughout the year to promote technology
transfer and university research. We also host visitors from other groups and institutions to discuss
best practices in technology transfer and economic development. Listed are highlights from FY2012.
(Black text notes TTO staff presentation/active participation)
JULY 2011
•Ciencia e Innovacion-Institute of the Americas
•Adoneh, LLC
•MP Healthcare Venture Management
•Patents & Patent Searching-UCSD Staff Education
•CONNECT Frontiers in Science and Technology –Back From
the Brink
•Biocom Open House
AUGUST 2011
•Department of Chemistry & Biochemistry-Faculty Outreach
•Licensing Executive Society (LES) Summer Social
•Department of Mechanical/Aerospace Engineering-Faculty
Outreach
•Department of Bioengineering-Faculty Outreach
•Calit2-Faculty Outreach
•Cellular and Molecular Medicine-Faculty Outreach
•Translational Medicine-Faculty Outreach
•Department of Medicine-Faculty Outreach
•UCSD Sharecase
SEPTEMBER 2011
•What It’s Like Being a CEO-Biocom
•Department of Anesthesiology-Faculty Outreach
•Health Sciences Business Development
•What is Left of the San Diego Biotech Industry?-Licensing
Executive Society (LES)
•Patent Nation: Web Conference Series – New U.S. Patent
Reform Law-Foley& Lardner LLP
•Althea Technologies and AltheaDx: Successfully Building Two
Biotech Companies-The Indus Entrepreneurs (TiE) SoCal
•Patents & Patent Searching-UCSD Staff Education
•Technology Transfer Roundtable-CONNECT
OCTOBER 2011
•Patent Reform Seminar-Morrison Foerster
•Patenting & Record Keeping-Division of Biological Sciences
•Stem Cell Science and Medicine in Our Community-CIRM
•Legal Update: New Patent Reform Law-Knobbe Martens
•Resources for Lab to Market-Rady School of Management
•Journeys in Discovery-Division of Biological Sciences
•CMRR Research Review-Center for Magnetic Recording
Research
•2nd Annual China Medical City Internation Expo-China Medical
City
•TPP Global Development (UK)
•Building Value into Technologies Before Licensing-Licensing
Executive Society (LES)
•TTO and Technology Transfer-Faculty Outreach
•Something Ventured-The Indus Entrepreneurs (TiE) South
Coast
•Licensing Panel-SDSU School of Business
•Department of Family and Preventative Medicine-Faculty
Outreach
NOVEMBER 2011
•Cenna Biosciences Open House
•UC System Intellectual Property Managers Meeting-UCOP
•Decade of Catalyzing Innovation Life Sciences Showcase-von
Liebig Entrepreneurism Center
•Patent Basics and Technology Transfer-Tau Beta Pi Honor Society, Engineering School
•Out of the Lab and Into the Market: Tech Transfer DemystifiedOklahoma Bioscience Institute and Greater Oklahoma City
Chamber
•Patents & Patent Searching-UCSD Staff Education
•Sanford Consortium “Collaboratory” Opening
•Stem Cell Meeting on the Mesa-Sanford Consortium for
Regenerative Medicine
DECEMBER 2011
•National Renewable Energy Lab (NREL) Tech Portal-von Liebig
Entrepreneurism Center
•Licensing Executive Society (LES)-San Diego Chapter Meeting
•CONNECT Policy Forum-US Patent and Trademark Office
JANUARY 2012
•Pathway to Discovery-Janssen Pharmaceuticals
•Open House-Janssen Pharmaceuticals
•Patents & Patent Searching-UCSD Staff Education
•10th Anniversary Celebration Technology Showcase-von Liebig
Entrepreneurism Center
•Technology Transfer Process: Center of Excellence for Stress
and Mental Health (CESAMH)-Faculty Outreach
FEBRUARY 2012
•Future Health-calit2
•Osage Partners
•Biosimilars - Wave of the Future or Child of the Privileged
Few?-Licensing Executive Society
•Personalized Medicine Symposium-Clearity Foundation
•Successful Women Biotech Executives: Opportunities &
Challenges-TiE South Coast
MARCH 2012
•Department of BioEngineering -Faculty Outreach
•Bio and Tech Converge-CONNECT
•US Patent Roundtable-Deputy Under Secretary of Commerce
for IP -Biocom
•10th Anniversary Celebration- 10 Years of Entrepreneurism-von
Liebig Entrepreneurism Center
•Department of Bioengineering-Faculty Outreach
•Department of-Faculty Outreach
•A New Approach to IP Management: The Penn State University
Research Model
•CleanTech/Clean Energy Technology Acceleration Program-von
Liebig Entrepreneurism Center
•Exit Strategies-TiE South Coast
FY2012 ANNUAL REPORT
Page 13
TTO organizes and participates in events and meetings throughout the year to promote technology
transfer and university research. We also host visitors from other groups and institutions to discuss
best practices in technology transfer and economic development. Listed are highlights from FY2012.
(Black text notes TTO staff presentation/active participation)
APRIL 2012
•Research Expo-Jacobs School of Engineering
•Patents & Patent Searching-UCSD Staff Education
•UCSD TTO Presentation to Executive MBA class, Rady School
of Management
•Open House-OCGA/COI/TTO
•Speed Dating: Finding Your Perfect Career Match?-American
Society for Biochemistry and Molecular Biology
•UC System Intellectual Property Managers Meeting
•Is there life (science) after Prometheus?-Licensing Executive
Society (LES)
•Connect with CONNECT
•Medical Device Summit West: Reducing Risk and Increasing
Return through Cutting-Edge Business Strategy and Technological Innovation
•National Innovation Showcase-2012 World TechConnect
•Department of Medicine-Faculty Outreach
•BIO International Convention-Boston, Massachusetts
MAY 2012
•Technology Licensing from the TTO and Entrepreneur
Viewpoints-SDSU School of Business
•von Liebig Entrepreneurism Center Seminar
•San Diego Incubators: Supporting Company Formation &
Development-TiE South Coast
•Department of Chemistry/ Biochemistry-Faculty Outreach
JUNE 2012
•UCSD TTO Presentation to Fulltime MBA class-Rady School of
Management
TTO Staff with Canadian Technology Transfer Delegation
Denise Lew, Senior Licensing Officer, at the California
Pavilion during the 2012 BIO International Convention held in
Boston, Massachusetts. BIO is one of the largest partnering
conference for the life science industry.
Saudi Delegation visit with Global CONNECT and TTO
Formal group and delegation visits
JULY 2011
•Apposite Capital LLP
•Shanghai Delegation
JANUARY 2012
•Ram Photonics Inc.
•Intellectual Property Exchange International (IPXI)
SEPTEMBER 2011
•Canadian Delegation on Intellectual Property Rights-US
State Department
FEBRUARY 2012
•Dow Chemicals
NOVEMBER 2011
•BADIR Technology Entrepreneurship Support Program in
Saudi Arabia-Global CONNECT
DECEMBER 2011
•Novo Nordisk
•Life Technologies
•Shire Pharmaceuticals
•Qualcomm Ventures
MARCH 2012
•Technology Transfer Best Practices-Arizona
MAY 2012
•Osage Partners
•Allied Minds
•City of San Francisco
•Miramar Ventures
•Innovega Inc.
Page 14
UC SAN DIEGO | TECHNOLOGY TRANSFER OFFICE
Local, National, and Global Impact
185 California Active Licenses
ALAMEDA (6)
Berkeley (2)
Emeryville (1)
Fremont (3)
CONTRA COSTA (1)
San Ramon (1)
LOS ANGELES (6)
Los Angeles (4)
Torrance (1)
Inglewood (1)
MARIN (2)
Novato (2)
MONTEREY (1)
Moss Landing (1)
ORANGE (4)
Anaheim (1)
Irvine (1)
Santa Ana (1)
San Juan Capistrano (1)
RIVERSIDE (1)
Temecula (1)
SACRAMENTO (1)
Sacramento (1)
(at the end of FY2012)
SAN DIEGO (121)
Carlsbad (12)
Del Mar (2)
La Jolla (26)
Oceanside (1)
Ramona (2)
San Diego (77)
Solana Beach (1)
SAN FRANCISCO (5)
San Francisco (5)
SAN MATEO (11)
Redwood City (1)
South San Francisco (8)
Brisbane (1)
Menlo Park (1)
SANTA BARBARA (1)
Santa Barbara (1)
127
San Diego
licenses
SANTA CLARA (13)
Palo Alto (2)
San Jose (4)
Santa Clara (2)
Los Gatos (2)
Mountain View (2)
Sunnyvale (1)
SANTA CRUZ (8)
Santa Cruz (7)
Scotts Valley (1)
VENTURA (3)
Thousand Oaks (2)
Camarillo (1)
YOLO COUNTY (1)
Davis (1)
Total Licenses
Statewide (185)
68%
in
San Diego
A select group of California companies that have licensed university technology over
the past several years:
FY2012 ANNUAL REPORT
Page 15
356
356 Active U.S. Licenses by State
active U.S.
licenses
356 Total U.S. Licenses
Alaska (1), Alabama (5), Arizona (5), California (185), Colorado (2), Connecticut (5), DC (1), Delaware (1),
Florida (2), Georgia (1), Iowa (2), Illinois (8), Indiana (2), Kentucky (1), Massachusetts (29), Maryland (6),
Michigan (3), Minnesota (5), Missouri (3), North Carolina (1), New Jersey (9), Nevada (1), New York (16),
Ohio (4), Oregon (1), Pennsylvania (8), Tennessee (2), Texas (9), Utah (2), Virginia (3), Washington (9),
Wisconsin (23), Wyoming (1)
405 Active Global Licenses by Country
2
405 Total Worldwide Licenses
ASIA: China (4), South Korea (1), Japan (8), Thailand (2), Taiwan (1)
AUSTRALIA: Australia (1)
EUROPE: Austria (2), Belgium (4), Denmark (2), France (2), Germany (1), Ireland (1), Italy (2), Netherlands (3), Switzerland (2), United Kingdom (9)
MIDDLE EAST: Israel (3)
NORTH AMERICA: Bermuda (1), United States (356)
Page 16
UC SAN DIEGO | TECHNOLOGY TRANSFER OFFICE
Technology Transfer
Results
94
U.S. patents
issued
AGREEMENTS
In FY2012, all agreements executed
totaled 702, nearly flat when compared
to 703 agreements executed in FY2011.
The agreements comprised licenses,
options, outgoing material transfers,
confidentiality, letters of intent, and other
administrative agreements. The pie chart
shows the distribution within the agreement types in FY2012.
702
total
agreements
FY2012-more than half of the agreements were transfers of research materials to the outside scientific community
INNOVATIONS REPORTED
32
40
64
59
63
65
96
322
314
334
345
373
364
428
FY03
FY04
FY05
FY06
FY07
FY08
FY09
The number of inventions, tangible research
materials (TRMs), and copyrights reported during
FY2012 was 481, compared to 416 reported during FY2011. For the fourth year in a row, innovations received surpassed the 400-mark. (In the
bar graph to the right, TRMs are shown in gold.)
137 «TRMs The distribution between life science and physical science innovations is similar to prior years,
133
98
approximately sixty percent life science and thirty
percent physical science. The total number of
404
416
481
active innovations in the San Diego portfolio was
FY10
FY11
FY12
more than 3,000 at the end of FY2012.
LICENSES
In FY2012, a total of 60 license agreements for
inventions and copyrights were finalized. In the last
eight-year period, the TTO executed between 60 and
85 licenses a year showing a strong level of sustained activity despite the economic downturn. The
TTO signed agreements with large, medium, and
small companies, including 12 startups founded on
university technology. The chart shows the distribution of licenses between inventions and copyrights.
41
56
71
71
85
82
66
60
64
60
FY03
FY04
FY05
FY06
FY07
FY08
FY09
FY10
FY11
FY12
FY2012 ANNUAL REPORT
Page 17
Patent Activity
The protection of university intellectual property is
crucial when companies are licensing technologies
and can often be critical when seeking financing for
new ventures. The total number of filed and issued
patents has increased from prior years. In FY2012,
94 U.S. patents issued compared to 88 issued patents in FY2011. Total U.S. filings in FY2012 were
247 compared to 239 in FY2011.
FY03
PATENTS
FY04
FY05
FY06
FY07
FY08
FY09
FY10
FY11
FY12
FY2003
FY2004
FY2005
FY2006
FY2007
FY2008
FY2009
FY2010
FY2011
FY2012
TOTALS
U.S. First Filings*
127
144
133
147
142
127
152
168
155
173
1,468
U.S. Secondary Filings**
45
44
39
35
65
85
73
83
84
74
627
First Foreign Filings***
69
94
67
89
60
53
61
54
58
75
680
Total Filed
241
282
239
271
267
265
286
305
297
322
2,775
U.S. Patents Issued
51
50
60
44
64
45
54
75
88
94
625
Foreign Patents Issued
69
79
87
148
62
116
97
39
46
70
813
Total Issued
120
129
147
192
126
161
151
114
134
164
1,438
* U.S. first filings are typically provisional filings, and some U.S. utility filings.
** U.S. secondary filings are conversions, continuations (includes divisionals, continuations-in-part), and refiled provisional patents.
*** First foreign filings are Patent Cooperation Treaty (PCT) filings.
Note: Foreign National Stage and U.S. National Stage filings are not included in the table above.
Some totals may change from year-to-year due to post fiscal year-end adjustments.
(in millions)
In FY2012, as is typical, patent prosecution
accounted for approximately half of the total for
expenditures. Nearly 64 percent of the patent
costs were reimbursed by licensees through
invention licensing agreements. The patent cost
reimbursement rate averaged 79 percent over
the last ten years. Typically, reimbursements
are recorded in a year following that in which
the costs were incurred. Please see the income
and expense charts on page 19.
Income
UCSD intellectual property
income increased in FY2012
to $19.6 million compared to
$18.7 million in FY2011. The
majority of licensing income was
from license issue fees, license
maintenance, milestone fees
and royalties. Legal cost reimbursements made up more than
17 percent of the total income in
FY2012. Detailed breakdowns
for income and expense are on
page 19.
(in millions)
Page 18
UC SAN DIEGO | TECHNOLOGY TRANSFER OFFICE
Mandatory Distributions of Income FY2003-FY2012
The Technology Transfer Office distributed approximately $9.5 million of intellectual property income in FY2012, compared to $14.2
million in FY2011. Distributions were made to inventors/authors, joint co-owners of intellectual property, participating academic units
for research support, the campus fund, and the UC General Fund in accordance with UC policies and UC San Diego campus guidelines. Invention and copyright income distributions are based on income received in the prior fiscal year (FY2011). Material transfer
agreement (MTA) income distribution is based on income received in the same fiscal year (FY2012).
(in thousands)
FY03
FY04
FY05
FY06
FY07
FY08
FY09
FY10
FY11
FY12
FY03-12
TOTALS
Inventor/
Author Share
$4,054
$2,654
$3,727
$6,192
$8,667
$8,609
$9,553
$9,142
$8,829
$5,752
$67,179
Joint
Titleholders
Share
$297
$295
$77
$393
$127
$398
$432
$466
$335
$403
$3,223
Research
Labs/ HAU*/
DEPT Share
$1,271
$1,126
$1,215
$1,747
$2,227
$2,299
$2,404
$2,279
$2,275
$1,506
$18,349
UC General
Fund Share†
-$1,219**
$1,007
$2,658
$3,382
$2,611
$3,470
$2,570
$2,744
$2,758***
$1,887
$21,868
Total
Distributions
$4,403
$5,082
$7,677
$11,714
$13,632
$14,776
$14,959
$14,631
$14,197
$9,548
$110,619
* Home Academic Unit (HAU).
** FY03 shows offset due to extraordinary legal expenses.
† Formerly called State General Fund.
*** Includes 2 years of charges for this fund.
Top-Earning Inventions The UC System reports the top-earning inventions
each fiscal year and in FY2012, three inventions from UC San Diego contributed to the top 25 inventions. The dollar amounts for these commercialized
inventions include royalty and fee income, but do not include patent/legal
reimbursements.
No. 3
EGF Receptor Antibodies
$7,925,000
head and oncology
neck cancer colorectal
cancer
No. 7
Firefly Luciferase
$3,011,000
No. 24
Tear Osmometer for Dry
Eye Disease Diagnosis
$444,000
bioluminescence
reporter assay reagent
enzyme
dry eye measurement
diagnostic
(search tags: copy and paste into
your search engine of choice)
FY2012 ANNUAL REPORT
Page 19
Intellectual Property Income & Expense FY2003-FY2012
UCSD’s technology transfer program incurred expenditures of
$10.9 million in FY2012 compared to $11.3 million for FY2011.
Approximately one-half of expenditures were incurred for patent
prosecution, of which approximately 64 percent was reimbursed
by licensees through licensing agreements.
UCSD intellectual property income increased in FY2012 to $19.6
million compared to $18.7 million in FY2011. The majority of
licensing income is from license issue fees, license maintenance
and milestone fees/royalties. With a primary mission to transfer
technology for the public good, TTO provides fair and equalaccess to available technologies and licenses to both large and
small companies that are best able to commercialize the innovations. When licensing to cash-strapped start-up companies, TTO
often receives equity in lieu of upfront fees to lower the entry
barriers for these fledgling business. In FY2012 approximately
$500,000 was recorded from a stock sale of a UCSD start-up that
was founded in 2003.
In addition, in FY2011, UCSD initiated a new tax on revenue
sources to generate campus operating revenue. This expense is
reported below as “Other Administrative Department Charges”
and is also known as the Auxiliary & Self Supporting Activities (ASSA) charge. The charge was $354,000 in FY2011 and
$238,000 in FY2012.
distributions
$9.5 million
income
(see page 18)
expenses
$19.6 million
$10.9 million
IP MANAGEMENT INCOME AND EXPENSE FY03-FY12 (in thousands)
I NCO M E
FY03
FY04
FY05
FY06
FY07
FY08
FY09
FY10
FY11
FY12
FY03-12
TOTALS
Invention
$6,368
$11,473
$15,496
$21,842
$21,423
$22,694
$22,235
$20,968
$14,048
$15,575
$172,122
Copyright
$157
$314
$214
$311
$219
$318
$236
$359
$347
$415
$2,890
Tangible Research
Material
$474
$405
$578
$310
$329
$586
$255
$281
$200
$171
$3,589
$3,678
$2,896
$5,396
$4,234
$4,080
$7,261
$4,397
$4,403
$4,164
$3,454
$43,963
-
-
-
$1
$193
$23
-
-
-
-
$218
$10,677
$15,088
$21,684
$26,699
$26,244
$30,882
$27,122
$26,011
$18,759
$19,615
$222,782
$4,029
$4,645
$6,132
$6,161
$6,336
$7,126
$6,263
$4,833
$5,036
$5,402
$55,963
$3
-
$4
-
-
-
-
-
-
-
$7
$1,981
$2,263
$2,272
$2,691
$2,732
$2,739
$3,079
$2,918
$3,072
$3,304
$27,051
-
-
-
-
-
-
-
-
$354
$238
$592
UCOP & OTT
Assessments
$902
$877
$892
$879
$461
$65
$65
$375
$65
$45
$4,626
Extraordinary
Expenses**
$6,567
$2,789
$459
$57
$205
$18
$3
-
-
-
$10,098
UC General Fund***
-$1,219
$1,007
$2,658
$3,382
$2,611
$3,470
$2,570
$2,744
$2,758
$1,887
$21,868
Total Expense
$12,263
$11,581
$12,417
$13,170
$12,345
$13,418
$11,980
$10,870
$11,285
$10,876
$120,205
NET INCOME
-$1,586
$3,507
$9,267
$13,529
$13,899
$17,464
$15,142
$15,141
$7,474
$8,739
$102,576
Legal Cost
Reimbursement
Extraordinary Income*
Total Income
EXPENSE
Patent Prosecution
Copyright
TTO Campus
Operations
Other Administrative
Department Charges ∂
* Extraordinary income includes nonrecurring items such as legal settlements and /or one-time payments.
** Extraordinary expenses includes unbudgeted expenses for litigation and settlement.
*** UC General Fund was previously called State General Fund.
† Includes 2 years of charges for this fund.
∂ New campus tax led to increased costs absorbed for intellectual property revenue for the past two fiscal years and moving forward.
†
technology transfer
Promotes and facilitates the transfer
of UC San Diego innovations for the
benefit of the University community
and the public.
TECHNOLOGY
TRANSFER OFFICE
9500 GILMAN DRIVE, MC 0910, LA JOLLA, CA 92093 | p: 858-534-5815 | f: 858-534-7345
HTTP://INVENT.UCSD.EDU